Olivier Huillard, Co-CEO at Areltys, Medical Oncologist at AP-HP, shared a post on LinkedIn:
“RLT in Oncology: Breakthrough innovation is here. But have we crossed the “Chasm”?
To my fellow clinicians, industry partners, and the entrepreneur community: we all know Everett Rogers Diffusion of Innovation curve. But for those of us in Radioligand Therapy (RLT), a crucial question remains: where exactly do we stand?
We’ve moved past the Innovators-those pioneering souls who managed I-131 and “home-brew” compounds for decades, treating RLT as much as an art as a science. A respectful wink to the “Theranostic Geeks” who laid the groundwork long before it was a trend!
My own journey in RLT as a medical oncologist started right there, working on thyroid cancer redifferentiation protocols-exploring the science behind these treatments when they were still a niche field. Today, with the arrival of Lu-PSMA, we have officially transitioned into the Early Adopter phase.
But between Early Adopters and the Early Majority lies the “Chasm” – Geoffrey Moore’s famous gap. To my entrepreneur friends: You know this moment. It’s the “make or break” pivot. It’s the stage where you must move from bespoke, cutting-edge experimentation to routine, industrial-scale delivery. As you know well: this is exactly where most innovations fail if they cannot scale.
In nuclear oncology, crossing this chasm isn’t a “one-click” fix. It requires building a bridge over four massive structural barriers. These are the exact pillars we are scaling at AP-HP, Assistance Publique – Hôpitaux de Paris, and they represent the core mission of Areltys:
- Smart Infrastructure: Moving beyond lead-lined walls to optimize existing capacity and orchestrate agile, data-driven expansion.
- Augmented Workforce: We need more hands, but we also need a workflow revolution to empower our physicians, radiopharmacists, physicists, nurses, and operators with tools that eliminate bottlenecks.
- Supply Chain Orchestration: Mastering the “just-in-time” ballet of short-lived isotopes at a global scale.
- Standardized Care Pathways: Harmonizing Theranostic Tumor Boards through digital coordination to ensure no patient is left behind.
At AP-HP, Assistance Publique – Hôpitaux de Paris, we see the skyrocketing demand daily.
This is why Areltys was created: to turn these clinical challenges into a scalable, industrial reality. We are building a vehicle specifically designed to help cross that Chasm.
What is your diagnosis? Are we still the passionate “early few,” or have we finally set foot in the Early Majority? And in your view, what remains the single biggest hurdle preventing us from making the leap?”
Other articles featuring Radioligand Therapy on OncoDaily.